Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TRK inhibitor
TSR-011 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Experimental Drug TSR-011 | EXPERIMENTAL | Experimental Drug TSR-011 |
| Name | Type | Description |
|---|---|---|
| TSR-011 | DRUG | Number of cycles until progression or unacceptable toxicity develops. |
Inclusion Criteria: * To be considered eligible to participate in this study, all of the following requirements must be met: 1. Patients in Phase 1 must have metastatic or locally advanced solid tumors who have failed to respond to standard therapy 2. All patients must have confirmation of eit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TSR-011 is an investigational small molecule being studied in adults with advanced solid tumors and lymphomas. It was evaluated in a Phase 1/2a dose escalation and cohort expansion trial in patients with these advanced cancers. It is not an approved therapy and remains in clinical development.
TSR-011 is being developed by GSK plc, which trades on the New York Stock Exchange under the ticker GSK. GSK holds the development program for this oral small molecule oncology candidate.
TSR-011 is in Phase 1 development. The single registered trial, NCT02048488, was a Phase 1/2a study that has been completed, and no trials are currently listed as active. The program remains investigational and has not been approved for any indication.
TSR-011 was studied in one trial, NCT02048488, titled a Phase I/IIa open-label dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lymphomas. It enrolled 72 patients across the United States, Poland, Spain, Taiwan, and the United Kingdom, and is completed.
NCT02048488 was an open-label, uncontrolled Phase 1/2a dose escalation and cohort expansion study of oral TSR-011 in patients aged 18 years and older with advanced solid tumors and lymphomas. It was not randomized and not blinded, and it enrolled 72 participants, including biomarker-selected patients.